Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals develops and commercializes products for central nervous system diseases. Commercial products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. Product candidates include SPN-830, SPN-817, SPN-820, SPN-443, SPN-446, and SPN-448. The company markets products through wholesalers, specialty pharmacies, and distributors. It was incorporated in 2005 and is headquartered in Rockville, Maryland.
Overview
Strengths
- With an appreciation Potential of 68.87%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Price to book ratio (1.68) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is -0.20 and it is lower than the sector mean.
- EV/EBITDA (9.88) is lower than the sector mean (51.86).
- EV/EBIT (17.39) is lower than the sector mean.
- Price to free cash flow (10.14) is lower than the sector mean.
- Strong EBITDA Margin of 26.02%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 23.5 |
| EV/EBITDA | 9.9 |
| Price/Free Cash Flow' | 10.1 |
| ROIC | 16.1% |
| Net Debt/EBITDA | -0.2 |